Cardiac Sarcoidosis with Life-Threatening Manifestations: When Second-Line Steroid-Sparing Therapy Has Not Controlled Myocardial Inflammation

This protocol covers rapidly progressive cardiac sarcoidosis presenting with life-threatening cardiac manifestations — including cardiogenic shock — in patients where the previous treatment line did not achieve the required reduction in active myocardial inflammation on follow-up cardiac FDG-PET.

Clinical scenario

Rapidly progressive cardiac sarcoidosis with life-threatening cardiac manifestations such as cardiogenic shock is among the most severe presentations of this disease. Early, aggressive management targets active granulomatous inflammation in the myocardium.

Previous treatment: failure condition

Prior therapy: A second-line steroid-sparing agent — such as methotrexate, mycophenolate, azathioprine, or leflunomide — added in combination with corticosteroids.

Goal not achieved: Cardiac FDG-PET at 2 to 6 months did not demonstrate minimal residual or resolved myocardial inflammation, indicating that inflammation remains insufficiently controlled and escalation is warranted.

Third-line approach

When cardiac FDG-PET continues to show active myocardial inflammation despite second-line combination therapy, a tumor necrosis factor-α–targeted agent may be considered as a third-line addition. Careful patient selection is required, with specific caution in patients with certain cardiac function profiles. The complete regimen, agent options, and monitoring guidance are detailed in the full protocol.

Treatment goal

Reduction in the degree of active granulomatous inflammation in the myocardium, assessed on cardiac FDG-PET imaging.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1161/CIR.0000000000001240

For those with life-threatening manifestations such as cardiogenic shock, higher initial corticosteroid doses, including intravenous doses of methylprednisolone of up to 1000 mg/d, can be prescribed until other causes of acute myocarditis (such as giant-cell myocarditis) are excluded.

If there is evidence of ongoing inflammation on follow-up FDG-PET, then tumor necrosis factor-α–targeted therapy with infliximab or adalimumab can be considered as a third-line agent.

Tumor necrosis factor-α–targeted therapy should be used cautiously in individuals with HF with reduced ejection fraction and New York Heart Association class III to IV symptoms because prior trials investigating these agents in HF suggested potential harm in patients with HF.

The response to treatment is measured in 2 ways: (1) improvement or resolution of the clinical presentation of arrhythmias, heart block, or HF and (2) reduction in the degree of active granulomatous inflammation in the myocardium.

View source ↗